AccuGenomics

The AccuGenomics team would like to thank our collaborators and clients for the support and discussions this week at the Association for Molecular Pathology (AMP) meeting in #Vancouver. #AMPATH24 We especially enjoyed meeting all of the new contacts working to develop and provide more accurate #NGS assays and tests as RUO or clinically validated assays. Exciting applications in liquid biopsy and other sample types. #CNV and #fusions were popular topics, as was the use of Internal Standards as a limit control for #ctDNA and #MRD. 4 posters are being presented this week, and a white paper on CNV’s. Contact us if you’d like to receive a PDF of any of these materials. Be sure to visit our Accukit ctDNA MRD IS commercialization partners LGC Clinical Diagnostics in their neighboring booth. Thank you for including the AccuGenomics team and science in the Corporate Workshop on Wednesday. There is still some time to meet with us in Booth 1630, grab a coffee and have a chat.

There is still time to meet with the AccuGenomics team if you are attending Association for Molecular Pathology (AMP) in Vancouver. Come hear how internal standards deliver confidence in the performance of every #NGS sample. Booth 1630. #AML #Myeloid #ctDNA #MRD

The AccuGenomics team is excited for this work and happy to support improved CNV calling in the Blackhawk Genomics NGS test. Improved accuracy means better patient outcomes.

The AccuGenomics team is excited for this line up of speakers and content during the LGC Clinical Diagnostics Corporate Workshop on Wednesday!

We are just 2 weeks away from the Association for Molecular Pathology (AMP) 2024 Annual Meeting & Expo! Here is a quick look at some of the featured content from AccuGenomics and our collaborators LGC Clinical Diagnostics, FRED HUTCHINSON CANCER RESEARCH, The Ottawa Hospital, Huntsman Cancer Institute, and Blackhawk Genomics. Will we see you there? Reach out to schedule some time with one of our experts to learn how internal standards for #NextGenerationSequencing will improve the accuracy and reproducibility of your #liquidbiopsy and #FFPE sample testing by #NGS. It's time to talk about #QC for #ctDNA and #MRD.

AccuGenomics is pleased to announce our partnership with LGC to improve cancer testing accuracy in Next Generation Sequencing (#NGS). This collaboration combines our patented NGS Internal Standards technology (SNAQ-Seq) with LGC’s expertise in quality control commercialization and distribution, enabling us to jointly deliver advanced molecular diagnostics and custom NGS reference materials for laboratories worldwide. Accukit ctDNA MRD IS and Accukit Myeloid DNA IS are now available for use as a per sample QC reference material in NGS testing to improve the accuracy of your data and support NGS assay validation. These materials are a superior alternative to positive control run samples, since they verify sample and assay performance for each target (i.e., measure the LOD for each sample, in every run, on any platform) to improve confidence in reporting to enhance patient management. Contact a member of the team for more information or product details. Together, we can improve the quality of sequencing data to power and inform treatment decisions for better patient outcomes. Click here to read more: https://lnkd.in/e95rEURG #CancerTesting #MRD #Sequencing #PrecisionMedicine #TreatmentResponse

It is a leap year, and maybe for #LBx too! February brought funding, several product launches, and new reimbursement coverage. Clinical and Regulatory The National Institutes of Health launched a clinical trials research network to evaluate the use of multi-cancer early detection tests. Additionally, February saw two Medicare coverage announcements, reimbursing LiquidHALLMARK in lung cancer and expanding Natera’s Signatera test for use in ovarian cancer and neoadjuvant breast cancer. Company Announcements & Product Launches Exact Sciences announced the launch of Riskguard hereditary cancer test in the United States. The Riskguard test provides an individualized patient report that includes gene specific and familial risks using a simple blood or saliva sample for 10 common cancers, including colorectal, breast, prostate, skin, ovarian, endometrial, pancreatic, gastric, kidney and endocrine. AccuGenomics launched the AccuKit Myeloid DNA IS as internal standards for NGS to enhance MRD for AML. Clinical Trials & Study Results Myriad Genetics and National Cancer Center Hospital East announced a collaboration on a pan-cancer MRD monitoring clinical trial, SCRUM-MONSTAR-SCREEN-3. REVEAL GENOMICS, S.L.’s HER2DX, a 27-gene expression liquid biopsy test for patients with early-stage HER2-positive breast cancer, is undergoing evaluation in a clinical trial being conducted by the Hospital Clinic Foundation for Biomedical Research and the consortium August Pi i Sunyer Biomedical Research Institute, or FCRB-IDIBAPS. M&A | VC | Private Equity | Legal Freenome raised $254 million in funding from existing and new investors, led by Roche, to advance its pipeline of single- and multi-cancer early detection tests. EValuate Diagnostics, a spinout of Hackensack Meridian Health Research Institute's Center for Discovery and Innovation (HMCDI) developing extracellular vesicle-based diagnostics for early detection of tumors and other diseases, obtained $1 million in venture capital funding. Pharus Diagnostics, a Taiwanese early cancer detection firm, acquired an exclusive worldwide license from the City of Hope for a series of blood-based molecular biomarkers that could potentially be used in the early diagnosis of pancreatic ductal adenocarcinoma (PDAC). Read the newsletter for more:?https://lnkd.in/gfXveHhS Sign up to receive our Liquid Biopsy Newsletter in your email: https://lnkd.in/gKQn7_zp The headlines have been handcrafted by Amal Thommil, Graham F., Nila Venkat, and Antony Awad #decibio #newsletter #cancerdetection #earlydetection #precisionmedicine #productlaunches #cancermonitoring #liquidbiopsytesting

AccuGenomics and collaborators from The Ottawa Hospital have released a white paper demonstrating improved #cnv calling by #ngs using the Thermofisher Oncomine Comprehensive Assay v3. Highlights are summarized below; we hope you have an opportunity to review the full PDF as you consider bringing dPCR level accuracy and precision to your NGS testing. Let's make NGS more accurate and more quantitative to improve decisions that impact patients. ? Internal standards (IS) reduce NGS testing bias to improved CNV detection as demonstrated a reduction of false negative and false positive calls when integrated into the Thermofisher Oncomine Comprehensive Assay v3. ? IS were designed to biochemically covary with ATM, BRCA1, BRCA2 & PALB2 exonic regions to allow precise exon abundance determination needed to detect copy loss (with accuracy and precision on par with dPCR but on your existing NGS platform). ? SNAQ?-SEQ IS gave exon level copy results for all six normal tissue and all nine tumor samples, compared to the standard Thermofisher OCAv3 pipeline that reported only half of these genes, with four of the missing OCAv3 calls coinciding with gene copy loss. ? SNAQ?-SEQ CNV detection was more robust and accurate than the existing OCAv3 method, routinely outperforming the OCAv3 pipeline, warranting moving forward with IS integration into the OCAv3 for testing of FFPE CNV. #ngs #cnv #sequencing #thermofisher #accuracymatters https://lnkd.in/eM6fJ4Ws

Introducing Accukit? Myeloid DNA IS Internal Standards for NGS to Empower AML Detection with Precision ? Ensure precision in detecting actionable Acute Myeloid Leukemia (AML) with Accukit? Myeloid DNA Internal Standards. Our innovative standards establish rigorous NGS quality control by validating assay and sample performance for every variant. ? Why choose Accukit? Myeloid DNA Internal Standards? 1. Enhanced QC Methodology: Internal Standards provide variant-specific sensitivity controls for therapeutically relevant AML targets,?proving?the?accuracy required for measurable residual disease (MRD) detection. 2. Universal Solution: Enable the monitoring of targeted next-generation sequencing (NGS) for AML patients across platforms, workflows, and samples. They serve as an independent control to ensure that the complex chemistry has met required assay sensitivity, for each sample. 3. Improved assay economics: Replace a costly external control,?lower test costs, increase throughput and flow cell utilization, and leverage a superior QC reagent. ? Choose Accukit? Myeloid DNA IS for accurate and reliable AML detection, learn more at the link below. ? #AML #NGS #Myeloid #PrecisionMedicine #mrd https://lnkd.in/eDZ-CS_f

Leverage the robust capabilities of NGS platforms to incorporate internal standards (IS) for enhanced detection of adventitious agents (AA). Establish a precise limit of detection for the assay to ensure accurate results and the ability to detect the AA if it is present. NGS stands out as a comprehensive analysis tool, and can be performed with a targeted collection of targets, or, deployed as an agnostic test. These approaches provide valuable insights into the presence of viral nucleic acids in test samples. NGS has proven to be a suitable replacement or supplement to traditional in vivo and in vitro culture-based tests. The latest ICH Q5A (R2) guidance advocates for the adoption of NGS as an appropriate substitute for in vivo viral detection, particularly when assessing cell banks and other critical starting materials. Additionally, NGS can resolve challenges associated with specific sample types that can otherwise require manipulation before adventitious viral testing, a common scenario in the manufacturing of traditional vaccines or adenovirus products. The ability to deploy an NGS assay for accurate and precise detection of adventitious agents will accelerate development timelines and QC release decisions, due to the efficiency and accuracy of the NGS process using internal standards.